Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP

Harrow, Inc. HROW

19 fiscal years on record · USD · FY2025 reported · SEC filings only
$272.3M
▲ 36.4% YoY
$-5.1M
$43.0M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

USD 272.3M
Revenue, FY2025 · full 19-year series below
Revenue $M Net income $M
FY2025 · Revenue 272.3 · Net income -5.1
100M200M
2007201020132016201920222025
Compound annual growth
+45.4%
+41.0%
+39.6%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +41.0% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−2 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating 11.2% · Net -1.9%
-20000%-40000%-60000%
200720162025
ROE
FY2025 · ROE -8.4%
50%100%-100%-200%
200720162025
Three returns, three denominators.

Each USD of equity lost 8 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 43.0
20M40M-10M-20M
200720162025
Net buybacks $M Dividends $M
FY2014 · Dividends · · Net buybacks 0.0
-5M-10M
20132014

Total assetsUSD 399.5M
EquityUSD 52.4M
CashUSD 72.9M
Gross debtUSD 250.0M
Net debtUSD 177.1M
Current ratio2.20×

Net debt stands at 338% of equity.

The 19-year record

19 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
HROW, 19-year financial record
Metric 2025202420232022202120202019201820172016201520142013201220112010200920082007
Revenue $B0.30.20.10.10.10.00.10.00.00.00.00.00.0◌◌◌◌◌◌
Operating income $B0.00.00.00.00.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0◌◌◌
EBITDA $B0.00.00.00.00.00.0−0.0◌−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0◌◌◌
Income tax $B0.00.00.00.00.00.00.0◌−0.0−0.00.00.0◌0.00.0◌◌◌◌
Net income $B−0.0−0.0−0.0−0.0−0.0−0.00.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B0.0−0.00.0−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0◌◌◌
EPS, diluted $−0.14−0.49−0.75−0.51−0.69−0.130.010.61−0.60−1.50−1.66−1.11−0.88−1.24−2.65−0.16◌◌◌
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend———————————————————
ROE %−8.4−24.9−49.6−72.5−93.6−12.20.6106.9−264.9——−87.0−60.9———−176.9−82.0−122.7
Shares out B0.040.040.040.030.030.030.030.020.020.020.010.010.010.010.020.02◌◌0.00

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 75 reconciliationsAUDITED

Reconciled in 19 of the 19 fiscal years we could check. 10 checks were skipped: cost of revenue is not tagged before 2017. Six checks were skipped: the balance sheet is not tagged before 2010. Four checks were skipped: the share count is not tagged before 2011.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2007

Share this section

Download image